| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |